Navigation Links
Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
Date:12/4/2007

t program evaluating the efficacy and safety of this novel biologic in the treatment of moderate to severe plaque psoriasis," said Jerome A. Boscia, M.D., senior vice president, Clinical R&D, Centocor, Inc. "We remain committed to developing safe and effective new therapies for patients with inflammatory diseases like psoriasis through continued research and development in disease areas where unmet needs in treatment remain."

About Psoriasis

Psoriasis is a chronic, immune-mediated disease, which results from the overproduction of skin cells resulting in their accumulation on the surface of the skin, which causes red, scaly plaques that may itch and bleed. It is estimated that approximately 7.5 million people in the United States and 10 million Europeans are living with psoriasis and nearly one-quarter of those people have cases that are considered moderate to severe.(1)

About Ustekinumab

Ustekinumab is a new, human monoclonal antibody in Phase 3 development by Centocor, Inc. for the treatment of moderate to severe plaque psoriasis, and is being investigated as an infrequently administered subcutaneous injection. Ustekinumab is a novel biologic therapy that targets interleukin 12 (IL-12) and interleukin 23 (IL-23), naturally occurring proteins that are important in regulating the immune system and that are also believed to play a role in immune-mediated inflammatory disorders.

Centocor discovered ustekinumab and has exclusive marketing rights to the product in the United States. Janssen-Cilag companies have exclusive marketing rights in all countries outside of the United States. Centocor, Inc. and the Janssen-Cilag companies are members of the Johnson & Johnson family of companies.

About Centocor, Inc.

Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of Crohn's dise
'/>"/>

SOURCE Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CLIA Waiver Submitted for Rapid HIV Test Employs StatSures Barrel Technology
2. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
3. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
4. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
5. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
6. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
7. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
10. CryoCor Receives FDA Approval for Right Atrial Flutter
11. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014  Unilife Corporation ("Unilife" ... announced today that it intends to release its financial ... ended June 30, 2014 after market trading ends on ... scheduled a conference call for 4:30 p.m. U.S. EDT ... at 6:30 a.m. AEST), to review the Company,s financial results, ...
(Date:8/29/2014)... CITY, Calif. , Aug. 29, 2014  Abaxis, ... company manufacturing point-of-care blood instrumentation and consumables to the ... Clint Severson , Chairman and Chief Executive Officer, will ... Best Ideas Conference 2014 on Tuesday, September 9, 2014 ... at the Omni Berkshire Place Hotel in ...
(Date:8/29/2014)... 29, 2014 Research and Markets  has ... Tissue Repair Devices Market 2014-2018" report to their ... mass of cells that connect, support, or surround bones. ... as tendons, ligaments, cartilage, fascia, and other fibrous tissues. ... tissues with age result in wear and tear in ...
Breaking Medicine Technology:Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
... Sequenom, Inc. (Nasdaq: SQNM ), today announced that ... interim chief financial officer effective November 10, 2009, reporting ... chairman of the board, Harry F. Hixson, Jr., Ph.D. ... the effective date of Mr. Maier,s appointment as interim ...
... Calif., Oct. 26 BioMarin Pharmaceutical Inc. (Nasdaq: ... acquired Huxley Pharmaceuticals, Inc. (Huxley), which has rights ... phosphate, for the rare autoimmune disease Lambert Eaton ... for Medicinal Products for Human Use of the ...
Cached Medicine Technology:Sequenom Announces Paul Maier to Become Interim Chief Financial Officer 2Sequenom Announces Paul Maier to Become Interim Chief Financial Officer 3BioMarin Acquires Huxley Pharmaceuticals, Inc. 2BioMarin Acquires Huxley Pharmaceuticals, Inc. 3BioMarin Acquires Huxley Pharmaceuticals, Inc. 4BioMarin Acquires Huxley Pharmaceuticals, Inc. 5BioMarin Acquires Huxley Pharmaceuticals, Inc. 6
(Date:8/29/2014)... 2014, 2 PM US Eastern Time)The current method ... antibodies, commonly produced in animals, to neutralize the ... safety to difficulties in developing, producing and maintaining ... research led by Charles Shoemaker, Ph.D., professor in ... at the Cummings School of Veterinary Medicine at ...
(Date:8/29/2014)... HealthDay Reporter THURSDAY, Aug. 28, ... babies are getting the vaccines they need to protect ... More than 90 percent of children are getting ... polio; hepatitis B and chickenpox (varicella), according to the ... vaccination among children 19 to 35 months of age ...
(Date:8/29/2014)... Edvance360, a leading provider of eLearning ... teaching, as well as 2011 winner and six-time-finalist for ... System, announced that Brooke Education Services, Northwest Academy, Typewell, ... Advertising Bureau of Canada (IAB Canada), StarSVCS, and HMG ... delighted to welcome each new client to the growing ...
(Date:8/29/2014)... School of Medicine have identified one way the Ebola ... that could lead to new therapies, in research ... & Microbe . , In work performed at Beamline ... researchers developed a detailed map of how a non-pathogenic ... takes signaling molecules in and out of the cell ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 The 8th Annual ... & Dine for a Cause, Pink Pooch Contest, Light of ... "Forget Me Knots" Pink Bow Campaign – all in support ... addition and twist this year…. Paint Columbus Pink Foam and ... at Cascade Hills, 727 54th Street, Columbus, Georgia 31904. It ...
Breaking Medicine News(10 mins):Health News:Mice study shows efficacy of new gene therapy approach for toxin exposures 2Health News:Most U.S. Babies Get Their Vaccines: CDC 2Health News:Most U.S. Babies Get Their Vaccines: CDC 3Health News:Edvance360 Continues to Experience Growth in Corporate, K-12, Health, and Non-Profit Sectors 2Health News:Paint Columbus Pink Cancer Awareness/Kick-Off Meeting for Anyone Interested in Participating 2
... People with bipolar,disorder and depression can find hope ... Health Care Decision Support system, available,through the Web site ... resources to support health decisions including:, -- ... depression;, -- links to online and ...
... Federal ... Regulation, ... the availability of DRA Tool(TM), a new feature of its,Sentinel RCM(TM) ... editing module that comprehensively supports the,additional reporting requirements of Section 6002 ...
... will showcase an,experimental model of a walking assist device ... with weakened leg muscles, at the,International Trade Fair on ... Disabled (BARRIER FREE 2008) which will be held at ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU095A ), Designed for people ...
... but nursing home study says risk greatest week after meds ... home patients who take antipsychotic drugs are 60 percent more ... who don,t take the drugs, a new study shows. , ... start taking the medications and gradually decreases, say Dutch researchers. ...
... surgeries has declined, so has death rate, study ... that perform fewer cardiac bypass operations don,t have more ... greater number of bypasses, a new study says. , ... hospitals that do more cardiac bypass operations have better ...
... for,Innovative Technology (CIT) today announced that CIT GAP ... Regeneration, LLC (STR), a medical,device company based in ... regeneration. CIT will invest $100,000., Joseph W. ... and counsel will help us begin developing the ...
Cached Medicine News:Health News:HAP Offers Web-Based Support for Depression and Bipolar Disorder 2Health News:HAP Offers Web-Based Support for Depression and Bipolar Disorder 3Health News:Sentry Data Systems Announces Deficit Reduction Act Compliance Tool 2Health News:Honda to Showcase Experimental Walking Assist Device 2Health News:Antipsychotic Drugs Linked to Pneumonia in Elderly 2Health News:Quality Care, Not Number of Procedures, Determines Bypass Results 2Health News:Quality Care, Not Number of Procedures, Determines Bypass Results 3Health News:CIT GAP Funds Invests in STR, LLC 2
... The Akbarnia PDR Instruments ... surgeons negotiate in and around ... and reconstruction procedures. The instruments ... construction, a variety of angled ...
... Concentrate System is a point-of-care system designed ... (also referred to as Platelet Rich Plasma ... from a small sample of blood. The ... factors, which are found in the platelets. ...
... II Platelet Concentrate System is a point-of-care ... Platelet Concentrate (also referred to as Platelet ... Plasma (PPP) from a small sample of ... body's natural growth factors, which are found ...
... Autologous growth factors (AGF) ... blood, the AGF gel delivers ... growth factors and proteins in ... the information of new bone ...
Medicine Products: